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Abstract
Background: The importance of Rumex genus and the renowned ethnopharmacological and biological potentials
of Rumex hastatus is evident from the previous reports. Recently the R. hastatus has been evaluated for anticancer
potential against HepG2, MCF7 or LNCaP cell lines with considerable cytotoxicity. We also reported the anti-tumor
and anti-angiogenic potentials of R. hastatus. The current study has been arranged to evaluate cytotoxic potential
of this plant against HeLa and NIH/3T3 cell lines and sort out the most active fraction of R. hastatus along with the
identification of bioactive compounds responsible for cytotoxicity.
Methods: The cytotoxic potential of methanolic extract and sub-fractions of R. hastatus was performed following (3-[4,
5-dimethylthiazole-2-yl]-2, 5-diphenyl-tetrazolium bromide) MTT calorimetric assay. Four concentrations (500, 250, 125
and 62.5 μg/ml) of each sample were used against both cell lines. Two cell lines i.e. HeLa and NIH/3T3 were used in
the assay. Furthermore, chemical characterization of chloroform fraction was performed by GC-MS analysis.
Results: The current investigational study demonstrates that all the solvent fractions of R. hastatus were active against
HeLa and NIH/3T3 cell lines. Among all the fractions, chloroform fraction was dominant in activity against both cell
lines. The observed IC50 values of chloroform fraction were 151.52 and 53.37 μg/ml against HeLa and NIH/3T3
respectively. The GC-MS analysis of chloroform fraction revealed the identification of 78 compounds with the
identification of bioactive ones like ar-tumerone, phytol, dihydrojasmone, sitostenone etc.
Conclusion: It can be concluded from our results that Rumex hastatus D. Don possess strong cytotoxic potential.
Moreover, the observed IC50 values and GC-MS analysis of chloroform fraction reveal that most of the bioactive
compounds are in chloroform fraction. It can be further deduce that the chloroform fraction is a suitable target for the
isolation of compounds having potential role in cancer therapy.
Keywords: Rumex hastatus, Cytotoxicity, Anticancer, HeLa, NIH/3T3, GC-MS
Abbreviations: eV, Electron volt; FBS, Fetal bovine serum; FID, Flame ionization detector; GC-MS, Gas chromatography-
mass spectrometry; HeLa, Human cervical carcinoma cell line or Henrietta Lacks cell line; HepG2, Human liver cancer
cell line/Hepatoblastoma G2 cell line; IC50, Median inhibitory concentration; LNCaP, Lymph node carcinoma of the
prostate; MTT, 3-[4, 5-dimethylthiazole-2-yl]-2, 5-diphenyl-tetrazolium bromide; MCF7, Breast cancer cell line/Michigan
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Cancer Foundation-7; NIH/3T3, Fibroblast cell line from Swiss mouse embryo/3-day transfer, inoculum 3 x 105 cells;
NIST, National Institute of Standards and Technology; OD, Optical density; Rh.Aq, Aqueous fraction; Rh.Chf, Chloroform
fraction; Rh.Cr, Methanolic extract of Rumex hastatus; Rh.EtAc, Ethyl acetate fraction; Rh.Hex, n-hexane fraction;
SEM, Standard error mean
Background
The leading research teams around the world are in con-
tinuous struggle to explore novel aspects to facilitate life.
The facilitation of life also encompasses decreased mor-
bidity and mortality [1]. One of leading causes of mortal-
ity is cancer worldwide which is considered as the most
challenging disease. Several factors have been reported
which cause cancer and hyper proliferative conditions
[2]. The free radicals induced lesions have been consid-
ered as one of the leading causes of cancer [3]. Attention
of the advanced clinical investigators has been focused
on the therapeutic measures of this disease. Various
therapeutic strategies are followed for the treatment of
cancer and chemotherapy has been considered as the
most acceptable and positive prognostic therapeutic ap-
proach [4]. The drugs from natural sources being bio-
degradable are preferred over the synthetic ones due to
their comparative safe and efficacious nature [5]. Several
natural anticancer drugs are available in the market like
etoposide, docetaxel, irinotecan, pacletaxel, topotecan,
vincristine and vinblastine [6]. Various derivatives of nat-
ural anticancer drugs are also being synthesized and
exploited against cancer [7]. The exploration of antican-
cer agent is not confined to the laboratory rather their
availability is also evidenced in plants, marine animals,
bacteria, algae, fungi, reptiles etc [8, 9]. The most feas-
ible and economic source of anticancer agents is plants.
Numerous anticancer compounds have been isolated
from plants and various investigators have reported
plethora of plants’ secondary metabolites with strong an-
ticancer potentials [10]. Several families of plants have
been reported to possess anticancer compounds. One of
the plants’ families i.e., Polygonaceae is also famous for anti-
cancer activities [11]. Rumex is one of the most important
genera of this family and several species of this genus have
been reported to possess strong anticancer potentials [12].
Several antitumor compounds have also been isolated from
different species of this genus, for example, Rumex hymeno-
sepalus has been reported with the isolation of antitumor
compounds, i.e. leucodelphinidin and leucopelargonidin
[13]. Several species of Rumex have been employed ethno-
medicinally in the treatment of inflammation, swelling,
hyper proliferative skin diseases [14].
Rumex hastatus is one of the most important species
which has been used traditionally for the treatment of
various ailments like rheumatism, tonsillitis, piles etc
[15–17]. Previously, the R. hastatus has been evaluated
for anticancer potential against HepG2, MCF7 or LNCaP
cell lines with considerable cytotoxicity [18]. Previously, R.
hastatus has been evaluated for anticholinesterase, anti-
oxidant, anti-tumor, anti-angiogenic, phytotoxic and anti-
bacterial potentials [19–22]. Based on the ethnomedicinal
uses and literature review of R. hastatus, the current study
was designed to explore cytotoxic potential of this plant
against cell lines and to find out the bioactive phytoconsti-
tuents responsible for anticancer activity using GC-MS
analysis.
Methods
Plant collection, extraction and fractionation
The aerial parts of mature plant of R. hastatus were
collected from the surrounding area of University of
Malakand, Pakistan. The plant’s name was confirmed
by Dr. Ali Hazrat, Plant Taxonomist, Department of
Botany, Shaheed Benazir Bhutto University, Sheringal
Dir (U), KPK, Pakistan, and deposited with voucher
specimen No. 1015SA. The plant’s material was shade
dried, powdered and subjected to maceration process.
Afterwards, it was filtered and the filtrate was evapo-
rated under reduced pressure using rotary evaporator
at 40 °C [23, 24]. Similarly, the crude methanolic extract
(Rh.Cr) was obtained weighing 400 g (5.7 %). The suspen-
sion of Rh.Cr weighing 300 g was subjected to fraction-
ation process with the order of increasing polarity. In this
way, the fractions obtained were 19 (6.3 %), 21 (7 %), 29
(9.6 %) and 120 (40 %) g of n-hexane (Rh.Hex), chloro-
form (Rh.Chf), ethyl acetate (Rh.EtAc) and aqueous frac-
tion (Rh.Aq) respectively [25, 26].
Gas Chromatography (GC) analysis
Samples were subjected to GC analysis using an Agilent
USB-393752 gas chromatograph (Agilent Technologies,
Palo Alto, CA, USA) with HHP-5MS 5 % phenylmethyl-
siloxane capillary column (30 m × 0.25 mm × 0.25 μm
film thickness; Restek, Bellefonte, PA) equipped with an
FID detector. The initial temperature of the oven was
retain at 70 °C for 1 min, followed by increase at the
rate of 6 °C/min to 180 °C for 5 min and finally at the
rate of 5 °C/min to 280 °C for 20 min. The temperature
of injector and detector were set at 220 and 290 °C,
correspondingly. Helium was used as carrier gas at a
flow rate of 1 ml/min, and diluted samples (1/1000 in
n-pentane, v/v) of 1.0 μl were injected manually in the
splitless mode.
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Gas Chromatography–Mass Spectrometry (GC/MS)
analysis
GC/MS analysis of samples were processed using an Agilent
USB-393752 gas chromatograph (Agilent Technologies,
Palo Alto, CA, USA) with a HHP-5MS 5 % phenylmethylsi-
loxane capillary column (30 m× 0.25 mm× 0.25 μm film
thickness; Restek, Bellefonte, PA) outfitted with an Agilent
HP-5973 mass selective detector in the electron impact
mode (Ionization energy: 70 eV) working under the same
experimental conditions as described for GC.
Identification of components
Compounds were recognized by comparison of their re-
tention times with those of authentic compounds in the
literature under the same set of conditions. Further identi-
fication were done through the spectral data obtained
from the Wiley and NIST libraries and further confirmed
by comparisons of the fragmentation pattern of the mass
spectra with data published in the literature [27, 28].
MTT assay on HeLa and NIH/3T3 cell lines
Cytotoxic activity of various samples of R. hastatus was
assayed in 96-well flat-bottomed micro plates following
the standard MTT (3-[4, 5-dimethylthiazole-2-yl]-2, 5-
diphenyl-tetrazolium bromide) colorimetric assay [29].
Briefly, HeLa cells (Cervical Cancer) and Mouse embry-
onic fibroblast NIH/3T3 cell lines were cultured in
Minimum Essential Medium Eagle. The media was sup-
plemented with 5 % of fetal bovine serum (FBS), 100 μg/
ml of streptomycin and 100 IU/ml of penicillin in
75 cm2 flasks and incubated in 5 % CO2 incubator at
37 °C. Growing cells were harvested exponentially and
counted with haemocytometer followed by dilution with
a particular medium. Cell culture was prepared having
the concentration of 6 x 104 cells/ml and transferred
(100 μl/well) into 96-well plates. After overnight incuba-
tion, medium was discarded and 200 μl of fresh medium
was added with various concentrations of plant samples
(1–30 μM). After 48 h, 200 μl MTT (0.5 mg/ml) was
added to each well and incubated additionally for 4 h.
Afterward, 100 μL of DMSO was added to each well.
The extent of MTT reduction to formazan within cells
was figured out by measuring the absorbance at 570 nm,
employing a micro plate reader (Spectra Max plus,
Molecular Devices, CA, USA). The samples causing
50 % growth inhibition for both cell lines were recorded
as IC50. The percent inhibition was calculated by the
formula given below;
% Inhibition ¼ 100− Mean OD of test sample−Mean OD of negative control
Mean OD of positive control−Mean OD of negative control
 100
The results i.e., Percent inhibition were processed via
Soft- Max Pro software (Molecular Device, USA).
Statistical analysis
All the tests were performed in triplicate and values
were expressed as means ± S.E.M. Multiple group com-
parison was performed by Two way ANOVA followed




The MTT assay was carried out against two types of cell
lines, i.e., HeLa and NIH/3T3. The crude methanolic ex-
tract and sub-fractions of R. hastatus were assay against
both cell lines. All the samples were found active against
both cell lines with chloroform fraction more dominant
as shown in Table 1. In HeLa cell line cytotoxicity assay,
the chloroform fraction revealed significant cytotoxic
potential. The observed cytotoxic potential against HeLe
cell line were 81.50 ± 0.86, 69.00 ± 2.80, 43.66 ± 0.89 and
34.22 ± 0.23 % at concentrations of 500, 250, 125 and
62.5 μg/ml respectively with IC50 value of 151.52 μg/ml.
Similarly, the second highest activity has been demon-
strated by ethyl acetate fraction i.e., 79.66 ± 0.89, 66.32 ±
1.30, 40.93 ± 0.49 and 29.83 ± 1.36 % cytotoxic activity at
concentrations of 500, 250, 125 and 62.5 μg/ml against
HeLa cell line with IC50 value of 166.50 μg/ml. The
methanolic extract and aqueous fraction demonstrated
moderate cytotoxic potentials with IC50 values of 347.33
and 369.68 μg/ml respectively. Among all the samples of
R. hastatus, the least activity was shown by that of n-
hexane fraction with IC50 of 572.61 μg/ml.
In NIH/3T3 cell line assay, again the chloroform frac-
tion was found dominant exhibiting 82.13 ± 0.88, 70.66
± 0.49, 64.02 ± 1.11 and 51.43 ± 0.61 % cytotoxic poten-
tial at concentrations of 500, 250, 125 and 62.5 μg/ml
with IC50 value of 53.37 μg/ml. Similarly, the ethyl acet-
ate fraction revealed the second highest activity against
NIH/3T3 cell line i.e., 72.76 ± 0.78, 59.00 ± 0.57, 46.86 ±
0.85 and 31.43 ± 0.81 % at concentrations of 500, 250,
125 and 62.5 μg/ml with IC50 value of 158.73 μg/ml.
The IC50 calculated for the rest of the samples were
174.52, 237.62 and 439.26 μg/ml for methanolic extract,
aqueous and n-hexane fractions respectively. The cyto-
toxic potential of all the test samples of R. hastatus
against NIH/3T3 cell line has been summarized in
Table 1. The standard drug doxorubicin exhibited IC50
value <0.1 μg/ml against both cell lines.
GC-MS analysis
Based on the high potency in both cell lines assays, the
chloroform fraction was subjected to GC-MS analysis.
A total of 78 phytoconstituents were identified by the
GC-MS analysis. The identified compounds contain
important bioactive compounds responsible for the
cytotoxic potential of the plant. The parameters of
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some compounds found in GC-MS analysis have been
summarized in the Table 2.
It is evident that area wise the highest percentage has
been exhibited by linoleic acid ethyl ester with retention
time 31.979 (96.29 %) followed by hexadecanoic acid,
ethyl ester with retention time 28.475 (94.9 %). A sum-
mary of all identified compounds in the chloroform frac-
tion has been shown in Table 3.
The GC-MS chromatogram of the chloroform fraction
is shown in Fig. 1 in which some of the important peaks
Table 2 Parameters of various components in Chloroform fraction of Rumex hastatus
RT (min) Height Height % Area Area % Area Sum % Base Peak m/z Width
26.577 536469 7.54 1916591 8.14 2.26 222 0.144
28.475 6E + 06 87.45 22348531 94.9 26.38 88 0.204
31.979 7E + 06 91.91 22675632 96.29 26.77 67.1 0.141
32.106 7E + 06 100 23550533 100 27.8 55.1 0.127
32.173 333815 4.69 496177 2.11 0.59 55.1 0.054
32.525 900308 12.66 2370371 10.07 2.8 88 0.107
34.939 467634 6.58 1286192 5.46 1.52 254 0.1
35.766 331299 4.66 836122 3.55 0.99 88 0.097
37.977 340828 4.79 773168 3.28 0.91 149 0.09
43.667 851097 11.97 2994991 12.72 3.54 43.2 0.134
Table 1 Cytotoxic activity of various samples of Rumex hastatus against HeLa and NIH/3T3 cell lines
Samples Conc.
(μg/ml)
HeLa Cell Line NIH/3T3 Cell Line
Inhibition (%) IC50 (μg/ml) Inhibition (%) IC50 (μg/ml)
Rh.Cr 500 63.25 ± 0.20*** 347.33 74.96 ± 0.21*** 174.52
250 41.43 ± 1.15*** 59.46 ± 0.54***
125 29.00 ± 1.50*** 43.07 ± 1.02***
62.5 20.64 ± 1.60*** 35.53 ± 0.61***
Rh.Hex 500 36.33 ± 3.50*** 572.61 53.86 ± 0.85*** 439.26
250 15.46 ± 2.43*** 40.60 ± 0.41***
125 07.33 ± 0.68*** 28.33 ± 0.33***
62.5 05.03 ± 0.23*** 21.50 ± 0.60***
Rh.Chf 500 81.50 ± 0.86*** 151.52 82.13 ± 0.88*** 53.37
250 69.00 ± 2.80*** 70.66 ± 0.49***
125 43.66 ± 0.89*** 64.02 ± 1.11***
62.5 34.22 ± 0.23*** 51.43 ± 0.61***
Rh.EtAc 500 79.66 ± 0.89*** 166.50 72.76 ± 0.78*** 158.73
250 66.32 ± 1.30*** 59.00 ± 0.57***
125 40.93 ± 0.49*** 46.86 ± 0.85***
62.5 29.83 ± 1.36*** 31.43 ± 0.81***
Rh.Aq 500 60.83 ± 1.36*** 369.68 65.60 ± 0.41*** 237.62
250 42.53 ± 0.46*** 51.96 ± 0.21***
125 33.61 ± 1.70*** 42.66 ± 0.49***
62.5 21.33 ± 0.33*** 36.13 ± 0.88***
Doxorubicin 500 96.63 ± 1.67 <0.1 98.53 ± 1.09 <0.1
250 91.87 ± 0.25 93.76 ± 0.78
125 89.46 ± 2.43 90.33 ± 0.88
62.5 84.50 ± 0.86 87.46 ± 0.54
Data is represented as mean ± S.E.M; n = 3, ***: P < 0.001
Key: Rh.Cr Crude methanolic extract, Rh.Hex n-hexane fraction, Rh.Chf chloroform fraction, Rh.EtAc ethyl acetate fraction, Rh.Aq aqueous fraction
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Table 3 List of compounds in chloroform fraction of Rumex hastatus
S. No Compound Label RT Common Name Formula Hits (DB)
1. Diethyl 2,2-Dihydroxy Sulfide 5.757 Tedegyl C4H10O2S 3
2. Benzenemethanol 6.438 Benzyl alcohol C7H8O 10
3. 2-Pyrrolidinone, 1-methyl 6.567 M-Pyrol C5H9NO 10
4. 4H-Pyran-4-one, 2,3-dihydro-3,5-dihydroxy-6-methyl- 8.793 NF C6H8O4 10
5. Benzoic acid, ammonium salt 9.343 Ammonium benzoate C7H6O2 10
6. 2-Methoxy-4-vinylphenol 12.609 p-Vinylguaiacol C9H10O2 10
7. Trimethylsilyl cyanide 15.284 Trimethyl silyl nitrile C4H9NSi 10
8. Bis(2-hydroxyethyl)lauramide 17.708 lauramide C16H33NO3 10
9. Dodecanoic acid, ethyl ester 18.281 Ethyl dodecanoate C14H28O2 10
10. 2-Cyclopenten-1-one, 3-methyl-2-pentyl 18.547 Dihydrojasmone C11H18O 10
11. Ethyl.alpha.-d-glucopyranoside 19.004 glucopyranoside C8H16O6 10
12. Silane, [(1,1-dimethyl-2 propenyl)oxy] dimethyl- 19.332 NF C7H16OSi 10
13. 4-[1,5-Dimethyl-1,4-Hexadienyl]-1-Methyl-1-Cyclohexene 19.582 NF C15H24 10
14. Ar-tumerone 19.755 Ar-tumerone C15H20O 10
15. 4-((1E)-3-Hydroxy-1-propenyl)-2-methoxyphenol 21.382 NF C10H12O3 10
16. Tetradecanoic acid 21.798 Myristic acid C14H28O2 10
17. (-)-Loliolide or Loliolide 22.21 Calendin C11H16O3 10
18. Tetradecanoic acid, ethyl ester 22.642 Ethyl myristate C16H32O2 10
19. 2-Cyclohexen-1-one, 4-hydroxy-3,5,6-trimethyl-4-(3-oxo-1-butenyl) 22.779 NF C13H18O3 10
20. p-Hydroxycinnamic acid, ethyl ester 23.832 p-Hydroxycinnamic acid, ethyl ester C11H12O3 10
21. 7,11,15-Trimethyl,3-Methylene-1-Hexadecene 24.028 Neophytadiene C20H38 10
22. 2-Pentadecanone, 6,10,14-trimethyl 24.223 Hexahydrofarnesyl acetone C18H36O 10
23. Pentadecanoic acid, ethyl ester 25.763 ethyl pentadecanoate C17H34O2 10
24. Ethyl (2E)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoate 26.577 NF C12H14O4 6
25. Hexadecanoic acid 27.756 Palmitic acid C16H32O2 10
26. Ethyl 9-Hexadecenoate 27.899 NF C18H34O2 10
27. 1,9-Tetradecadiene 28.273 NF C14H26 10
28. Hexadecanoic acid, ethyl ester 28.475 Ethyl palmitate C18H36O2 10
29. (E)-3-(4-Biphenylyl)-2-propen-1-ol 28.518 NF C15H14O 8
30. Peniopholide 29.798 Peniopholide C15H24O3 10
31. Heptadecanoic acid, ethyl ester 30.025 Ethyl n-heptadecanoate C19H38O2 10
32. Propyl hexadecanoate 30.527 Propyl palmitate C19H38O2 10
33. Heptadecanoic acid, ethyl ester 30.607 Ethyl n-eptadecanoate C19H38O2 10
34. 2-Hexadecen-1-ol, 3,7,11,15-tetramethyl-, [R-[R*,R*-(E)]]- 31.016 Phytol C20H40O 10
35. cis-9,cis-12-Octadecadienoic acid 31.507 NF C18H32O2 10
36. E-11,13-Tetradecadien-1-ol 31.616 NF C14H26O 10
37. Linoleic acid ethyl ester 31.979 Mandenol C20H36O2 10
38. Ethyl 9-Octadecanoate 32.104 Ethyl 9-Octadecenoate C20H38O2 10
39. exo-4-Methylbicyclo[3.2.1]octan-3-ene 32.121 NF C9H14 10
40. 16-Methyloxacyclohexadeca-3,5-dien-2-one 33.111 NF C16H26O2 10
41. 3.beta.-Hydroxydihydroconfertifolin 33.956 NF C15H24O3 1
42. Ethyl 9-Hexadecenoate 34.021 NF C18H34O2 10
43. Cis-8-methyl-exo-tricyclo[5.2.1.0(2.6)]decane 34.647 NF C11H18 10
44. 9,10-Anthracenedione, 1,8-dihydroxy-3-methyl 34.942 C.I. Natural Yellow 23 C15H10O4 10
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are clearly visible. Some important bioactive com-
pounds which having a positive role in cytotoxicity are
sorted in Fig. 2. Moreover, the integration patterns of
some important compounds as elucidated by GC-MS
are shown in Fig. 3.
Discussion
HeLa is a type of immortal cell line obtained from cer-
vical cancer cells and for the very first time this cell line
has been taken from late Henrietta Lacks in 1951 and
abbreviated for her name [30]. Similarly, the NIH/3T3
cell line was originated from swiss mice in 1962 which
consists of immortal fibroblast cell and widely used for
experimental purposes [31]. To figure out the cytotox-
icity in these cells, the MTT assay is considered as a
rapid and authentic procedure to appraise the cell viabil-
ity and death by calorimetric analysis [29]. Previously,
the MTT assay has been reported by numerous re-
searchers to evaluate the cytotoxicity [32, 33]. Recently,
Polygonum hydropiper has been demonstrated with sig-
nificant cytotoxicity against NIH/3T3 cell line following
MTT assay [34]. As this is evidenced from several
Table 3 List of compounds in chloroform fraction of Rumex hastatus (Continued)
45. 4,8,12-Trimethyltridecan-4-olide 35.181 NF C16H30O2 10
46. 5-Icosyne 35.305 5-Eicosyne C20H38 10
47. Ethyl 9-Hexadecenoate 35.382 NF C18H34O2 10
48. Heptadecanoic acid, ethyl ester 35.768 NF C19H38O2 10
49. 13-Tetradecenal 35.985 NF C14H26O 10
50. 5-Dodecyne 36.078 5-Dodecyne C12H22 10
51. N-Vanillylnonanoamide 37.013 Nonivamide C17H27NO3 10
52. 1,2-Benzenedicarboxylic acid, bis (2 ethylhexyl) ester 37.978 DNOP C24H38O4 10
53. N(4-Hydroxy-3-Methoxybenzyl)-8-Methylnon-6-Enamide 38.186 NF C18H27NO3 10
54. delta.13-cis-Docosenoic acid 38.242 Erucic acid C22H42O2 10
55. N-(4-Hydroxy-3-Methoxybenzyl)-8-Methyl-Nonanamide 38.489 NF C18H29NO3 10
56. Docosanoic acid, ethyl ester 38.566 Ethyl docosanoate C24H48O2 10
57. 9,10-Anthracenedione, 1,8-dihydroxy-3-methoxy-6-methyl 39.322 Physcion C16H12O5 10
58. Methyl palustrate isomer 39.554 Methyl palustrate C21H32O2 1
59. 1-Bromo-4,8,12-trimethyl-3(E),7(E)-11-tridecatriene 40.642 NF C16H27Br 5
60. Oleic acid amide 40.909 Oleamide C18H35NO 10
61. Heptadecanoic acid, ethyl ester 41.07 NF C19H38O2 10
62. 1,1-Di(1,1-dimethylethyl)cyclopropane 41.672 NF C11H22 3
63. Arachic alcohol 41.685 n-Eicosanol C20H42O 10
64. Aristol-9-en-8-one 42.368 Aristolone C15H22O 10
65. 2-Bromotetradecane 42.397 NF C14H29Br 10
66. Stigmasta-5,22-dien-3-ol, acetate, (3.beta.,22Z)- 42.529 NF C31H50O2 10
67. Stigmast-5-en-3-ol, (3.beta.,24S)- (CAS) 42.968 Clionasterol C29H50O 10
68. 7-methyltocol 43.226 NF C27H46O2 2
69. Stigmast-5-en-3-ol, acetate, (3.beta.)- 43.666 β-Sitosterol acetate C31H52O2 10
70. alpha.-Tocopherol 44.466 Vitamin E C29H50O2 7
71. Cholesta-4,6-dien-3-ol, benzoate, (3.beta.) 45.533 NF C34H48O2 9
72. Alpha.-Bisabolol 52.989 .Alpha.-bisabolol C18H32O 10
73. Methyl Commate E 53.773 NF C31H50O5 10
74. Stigmast-4-en-3-one 55.721 Sitostenone C29H48O 10
75. 2-Ethylthio-2-ethoxy-3-oxo-N phenylbutanamide 57.414 NF C14H19NO3S 9
76. 3-(Methoxymethoxy)-5-(phenylmethoxypentanal 58.739 NF C14H20O4 1
77. 13-Epimanool 62.472 Epimanool- C20H34O 10
78. 1,2-Dicyclohexyl-1,1,2,2-tetrafluoroethane 70.638 NF C14H22F4 6
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reports that a specific pharmacological potential within
plant species is basically conferred due to specific group
of compounds [35]. Similarly, a specific group of phytocon-
stituents is responsible for the cytotoxic potential of certain
plants [36]. The GC-MS is a quick and easy way of finding
out various components in a crude mixture of plant extract
[37]. In our current research, the GC-MS analysis of chloro-
form fraction of R. hastatus showed 78 compounds summa-
rized in Table 2. Several compounds identified by GC-MS
in the chloroform fraction are reported to have positive role
in cell toxicities. For instance, phytol, dihydrojasmone, ethyl
α-d-glucopyranoside, anthracenedione, silane, nonivamide,
eicosanol, aristolone, ar-tumerone and sitostenone are the
compounds with cytotoxic/anticancer potential demon-
strated along with their spectra in Figs. 2 and 3.
Phytol present in R. hastatus has been reported to in-
duce programmed cell death in human lymphoid leukemia
Molt 4B cells [38]. Dihydrojasmone, one of the member of
jasmonate family, which has been implied as a new family
of anticancer agents [39]. Ethyl-α-d-glucopyranoside a de-
rivative of glucopyranoside has been reported time and
again to possess strong anticancer potential and it is
Fig. 1 GC-MS chromatogram of chloroform fraction of Rumex hastatus
Fig. 2 Structures of some anticancer compounds identified in the GC-MS analysis of chloroform fraction of Rumex hastatus. a Phytol b Dihydrojasmone
c Ethyl.alpha.-d-glucopyranoside d Anthracenedione e Nonivamide f Silane g Eicosanol h Aristolone i 2-Ethylthio-2-ethoxy-3-oxo-N-phenylbutanamide
and j Sitostenone
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evident from the GC-MS analysis that R. hastatus contain
ethyl α-d-glucopyranoside, which may confer the possible
anticancer potential to this plant. Anthracenedione has
also been reported to possess anticancer properties [40].
Silane has been proven as an efficient agent in a nanoparti-
cle based drug delivery system for anticancer compounds.
The chloroform fraction of R. hastatus also possess noni-
vamide, which is skin permeation enhancer and used in
various ointments etc [41]. Similarly, eicosanol is a C20 al-
cohol present in R. hastatus and C20 aliphatic alcohols has
been employed in the treatment of hyperproliferative skin
disordersone [42]. Aristolone and Ar-tumerone are sesqui-
terpenes, and the derivatives of sesquiterpene have been
reported to possess the cytotoxic potential [43]. Likewise,
vitamin E a phenolic compound with pronounced free
radical scavenging and anticancer potential has also been
evidenced from Table 2 [44, 45]. Another compound i.e., a
natural steroid named sitostenone has also been analyzed
in GC-MS spectra and steroids have also been used since
long for the treatment of cancer, so this compound may
also be involved in cytotoxicity observed in our current
studies [46]. The current investigational study demonstrates
Fig. 3 GC-MS spectra of some important compounds in chloroform fraction of Rumex hastatus
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that the chloroform fraction of R. hastatus was the most ac-
tive one against two types of cell lines. The regression and
correlation analysis shows that this plant has a parallel cyto-
toxic potential against both the cell lines as depicted in the
Fig. 4 with r2 value of 0.881. The current study can also be
correlated with the previous cytotoxic activity of R. hastatus
against brine shrimps in which the chloroform fraction was
the most active fraction [22]. Based on the marked potential
of this fraction, it has been chemically characterized and
based on the literature survey; the active compounds have
been sorted out.
Conclusion
Based on our current results, we can conclude that Rumex
hastatus is a potential source of cytotoxic compounds.
Moreover, the chloroform fraction is the active one among
other solvent fractions of R. hastatus. Based on the GC-
MS analysis of chloroform fraction, we can conclude that
the chloroform fraction of R. hastatus is a rich source of
bioactive compounds responsible for cytotoxicity.
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